ICY Stock Overview
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ICY from our risk checks.
Incyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.11 |
| 52 Week High | US$68.70 |
| 52 Week Low | US$47.11 |
| Beta | 0.67 |
| 1 Month Change | -10.95% |
| 3 Month Change | -15.72% |
| 1 Year Change | -29.05% |
| 3 Year Change | -32.78% |
| 5 Year Change | -34.30% |
| Change since IPO | 196.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| ICY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.4% | -0.2% | 0.5% |
| 1Y | -29.1% | -22.8% | 1.3% |
Return vs Industry: ICY underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: ICY underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| ICY volatility | |
|---|---|
| ICY Average Weekly Movement | 2.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ICY has not had significant price volatility in the past 3 months.
Volatility Over Time: ICY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,524 | Herve Hoppenot | www.incyte.com |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
Incyte Corporation Fundamentals Summary
| ICY fundamental statistics | |
|---|---|
| Market cap | €10.83b |
| Earnings (TTM) | €557.08m |
| Revenue (TTM) | €3.45b |
19.2x
P/E Ratio3.1x
P/S RatioIs ICY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICY income statement (TTM) | |
|---|---|
| Revenue | US$3.70b |
| Cost of Revenue | US$1.88b |
| Gross Profit | US$1.81b |
| Other Expenses | US$1.21b |
| Earnings | US$597.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 2.66 |
| Gross Margin | 49.00% |
| Net Profit Margin | 16.17% |
| Debt/Equity Ratio | 0% |
How did ICY perform over the long term?
See historical performance and comparison